- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05210621
LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB (CONSONANCE EX)
LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS: CONSONANCE EXTENSION STUDY
The study duration of 4 years was considered to be sufficient to show a reliable and relevant effect of ocrelizumab on disability progression in the main study (CONSONANCE). However, given the potential long-term use of ocrelizumab in patients with progressive MS, it is critical that additional effectiveness and safety data are accrued in this patient population. In particular, understanding how ocrelizumab can prevent or delay time to major disability milestones such as the need to use an assisting device (Expanded Disability Status Scale [EDSS] 6.0) or a wheelchair (EDSS ≥7.0) is of significant relevance, given that progression to such milestones is associated with a significant reduction in patients' quality of life and an increase in cost of treatment (Kobelt et al. 2017).
In the ORATORIO trial, ocrelizumab reduced the risk of 24-week confirmed EDSS ≥7.0 by 46% (hazard ratio [HR]: 0.54, 95% CI 0.31-0.92; p = 0.022) in patients with primary progressive multiple sclerosis (PPMS). To further characterize the potential long-term impact of ocrelizumab treatment on time to 24-week confirmed EDSS ≥7.0, an analysis was used to extrapolate the observed data into the future, estimating the time at which 50% of patients were expected to have reached EDSS ≥7.0. Extrapolated median time to confirmed EDSS ≥7.0 was 12.1 years for placebo, which was similar to the actual median time observed in MSBase (12.4 years), and 19.2 years for ocrelizumab, representing a 7.1-year delay (95% CI: -4.3 to 18.4) [Butzkueven et al 2021]. A recent MSBase analysis also showed that in a cohort of patients with secondary progressive MS (SPMS), 17.9% reached a confirmed EDSS score of 7.0 from the diagnosis of SPMS, over a period of approximately 12 years (Lizak et al. 2020). Therefore, following patients who complete CONSONANCE beyond the 4-year study period is justified, to better assess the impact of ocrelizumab on these long-term disability milestones.
Another important therapeutic clinical goal in patients with progressive MS is preserving upper limb function. Patients with progressive MS with high EDSS scores, including those who are wheelchair-restricted, experience a devastating reduction in quality of life if they lose any residual function in their arms and/or hands, as this affects the level of independence and significantly limits the ability to perform activities of daily living (Kraft et al. 2014). The Nine-Hole Peg Test (9-HPT) has become one of the most frequently used measures of upper extremity function in MS (Earhart et al. 2011). A 20% worsening in test time is commonly used to define clinically meaningful worsening, as it corresponds to predefined clinically significant changes of established clinician- and patient-reported measures (Feys et al. 2017). Progression rates are lower for 9-HPT compared to EDSS or the Timed 25-Foot Walk Test (25FWT; Goldman et al. 2019). Therefore, following patients who complete CONSONANCE beyond the 4 year study period is justified, to better assess the long-term impact of ocrelizumab on preserving upper limb function.
Patients with MS who have completed the CONSONANCE study, and have a favorable benefit risk ratio, as determined by the treating neurologist, can be included in this study if they meet the inclusion and exclusion criteria.
1.1. Study design
This is a 4-year, single-arm, open-label, multicenter study for patients who have completed 192 weeks of treatment with ocrelizumab in the CONSONANCE study (NCT03523858), and enrolled under the protocol version 1 of CONSONANCE. It is estimated that the study will enroll approximately 90 patients with progressive MS. The study will consist of the following periods:
- Screening period: The screening visit should be scheduled up to two weeks before the first infusion of ocrelizumab, and always after the last visit of CONSONANCE at Week 192. This period should not be exceeded.
- Treatment period: The first visit of the treatment period (first infusion of ocrelizumab) will occur at the baseline visit, which should be 24 weeks (+14 days) after the last infusion of ocrelizumab in CONSONANCE. Ocrelizumab will be administered every 24 weeks up to Week 168 of this study. The last visit in the treatment period will be conducted 24 weeks after the last dose of ocrelizumab (i.e., at Week 192).
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Céline CALLIER
- Phone Number: 33 4 92 03 78 98
- Email: callier.c@chu-nice.Fr
Study Contact Backup
- Name: Christine Lebrun-Frenay
- Phone Number: 33 4 92 03 78 98
- Email: lebrun-frenay.c@chu-nice.fr
Study Locations
-
-
-
Amiens, France, 80051
- Not yet recruiting
- Amiens University Hospital
-
Contact:
- Abdullatif AL KHEDR
- Email: alkhedr.abdullatif@chu-amiens.fr
-
Bayonne, France, 64100
- Not yet recruiting
- Bayonne Hospital
-
Contact:
- Patricia Bernady
- Email: pbernady@ch-cotebasque.fr
-
Principal Investigator:
- Patricia Bernady
-
Bordeaux, France, 33076
- Not yet recruiting
- Bordeaux University Hospital
-
Caen, France, 14033
- Not yet recruiting
- CAEN University Hospital
-
Contact:
- pierre Branger
- Email: branger-p@chu-caen.fr
-
Principal Investigator:
- Pierre Branger
-
Clermont-Ferrand, France, 63003
- Not yet recruiting
- Clermont Ferrand university hospital
-
Lille, France, 59037
- Not yet recruiting
- Lille University Hospital
-
Contact:
- Patrick Vermersch
- Email: patrick.vermersch@univ-lille2.fr
-
Lyon, France, 69677
- Not yet recruiting
- Lyon university hospital
-
Marseille, France, 13385
- Not yet recruiting
- Marseille Univesity Hospital
-
Montpellier, France, 34295
- Not yet recruiting
- Montpellier University Hospital
-
Contact:
- Pierre Labauge
- Email: labauge@yahoo.fr
-
Nancy, France, 54000
- Recruiting
- Nancy University Hospital
-
Contact:
- Guillaume Mathey
- Email: gmathey@chru-nancy.fr
-
Principal Investigator:
- Guillaume Mathey
-
Nantes, France, 42055
- Not yet recruiting
- Nantes University Hospital
-
Contact:
- david Laplaud
- Email: david.laplaud@univ-nantes.fr
-
Nice, France, 06000
- Recruiting
- Nice University Hospital
-
Contact:
- Céline CALLIER
- Phone Number: 33 4 92 03 78 98
- Email: callier.c@chu-nice.Fr
-
Contact:
- Christine LEBRIN-FRENAY
- Phone Number: 33 4 92 03 78 98
- Email: lebrun-frenay.c@chu-nice.fr
-
Principal Investigator:
- Christine LEBRUN FREANY
-
Nîmes, France, 30900
- Not yet recruiting
- Nîmes University Hospital
-
Contact:
- Giovanni Castelnovo
- Email: giovanni.castelnovo@chu-nimes.fr
-
Rennes, France, 35033
- Not yet recruiting
- Rennes University Hospital
-
Strasbourg, France, 67000
- Not yet recruiting
- Strasbourg university hospital
-
Contact:
- Jerome De Seze
- Email: erome.DESEZE@chru-strasbourg.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent form
- Able to comply with the study protocol, in the investigator's judgment
- Affiliation to the social security system
- Completed the treatment period of Roche-sponsored ocrelizumab trial (CONSONANCE) and who in the opinion of the investigator may benefit from treatment with ocrelizumab. Only patients enrolled under Protocol version 1 (approval date: 18 February 2018) will be eligible.
- Meet re-treatment criteria with ocrelizumab (please see section 6.11)
- Patients who became pregnant by chance between the last visit of the CONSONANCE study and screening of this study, as confirmed by pregnancy tests at screening, will enter the study but will only re-start treatment with ocrelizumab after birth or after breastfeeding is stopped, as per re-treatment criteria in section 6.11
Women of childbearing potential* (WOCBP):
- Must have a negative urine pregnancy test at Visit 1 (Screening) and Visit 2 (Baseline)
- Must agree to remain abstinent or use an acceptable birth control method during the treatment period and for at least 6 months or longer after the final dose of ocrelizumab, as applicable in the ocrelizumab package leaflet. The following contraceptive methods are considered acceptable (failure rate >1% [Clinical Trial Facilitation Group (CTFG)]): (1) progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action; (2) male or female condom with or without spermicide; (3) cap, diaphragm, or sponge with spermicide; (4) combination of male condom with cap, diaphragm, or sponge with spermicide (double-barrier method). Birth control methods that are highly effective (i.e. failure rate <1% [CTFG]) may also be used but are not required, and include: (1) oral, intravaginal or transdermal combined hormonal contraception associated with inhibition of ovulation; (2) oral, injectable or implantable progestogen-only hormonal contraception associated with inhibition of ovulation; (3) intrauterine device; (4) intrauterine hormone-releasing system; (5) bilateral tubal occlusion; (6) vasectomized partner; (7) sexual abstinence.
Exclusion Criteria:
- Hypersensitivity to ocrelizumab or any of its excipients
- Patients in a severely immunocompromised state, until the condition resolves
- Evidence of any adverse event (AE) potentially attributable to ocrelizumab, for which the local label recommends permanent discontinuation
- Existence of a contra-indication as per the Summary of Product Characteristics (SmPC)
- Prohibited concomitant medication as specified in section 6.7
- Patients intending to become pregnant during the study or within 6 months after the last dose of the study drug in CONSONANCE
- Patients who had early ocrelizumab discontinuation in CONSONANCE (exemption made for treatment discontinuation due to unplanned pregnancy and breastfeeding for patients who continued clinical study assessments in CONSONANCE)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Patients with MS who have completed the CONSONANCE study
|
ocrelizumab will be administered as single 600-mg infusions in 500 mL 0.9% sodium chloride every 24 weeks (±14 days) up to Week 192 (Year 4) of this study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with upper limb disability progression
Time Frame: baseline
|
Proportion of patients with upper limb disability progression, defined as the proportion of patients with ≥20% worsening in 9 HPT score confirmed for at least 24 weeks,
|
baseline
|
Proportion of patients with upper limb disability progression
Time Frame: week 192.
|
Proportion of patients with upper limb disability progression, defined as the proportion of patients with ≥20% worsening in 9 HPT score confirmed for at least 24 weeks,
|
week 192.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-PP-23
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
Clinical Trials on Ocrelizumab
-
Hoffmann-La RocheCompleted
-
Johns Hopkins UniversityGlaxoSmithKlineTerminatedMultiple SclerosisUnited States
-
CinnagenCompletedMultiple Sclerosis | Relapsing-RemittingIran, Islamic Republic of
-
Wayne State UniversityRecruitingMultiple Sclerosis, Relapsing-RemittingUnited States
-
Fondation Ophtalmologique Adolphe de RothschildRecruiting
-
University of Colorado, DenverGenentech, Inc.Recruiting
-
Genentech, Inc.Completed
-
National Institute of Allergy and Infectious Diseases...Genentech, Inc.; Rho Federal Systems Division, Inc.; Autoimmunity Centers of...RecruitingMultiple SclerosisUnited States
-
Genentech, Inc.Completed